KLRD1 and breast carcinoma: Other strategies to interfere with HLA class I inhibition could include monoclonal antibodies that block inhibitory receptors on NK cells, such as monalizumab, or genetically modified NK cells to reduce expression of inhibitory NK cell receptors, as this would reduce the threshold for NK cell activation and may contribute to the development of curative immunotherapeutic strategies for breast cancer patients.